Anti-Mouse IFN Beta Antibody (MIB-5E9.1)
Based on 1 Customer Validation
Anti-Mouse IFN Beta Antibody (MIB-5E9.1) is an antibody targeting mouse IFN-β. Anti-Mouse IFN Beta Antibody (MIB-5E9.1) blocks the IFN-β signaling pathway, abolishes LPS-induced upregulation of B7H1 and GITRL in dendritic cells, restores dendritic cell-dependent T cell proliferation impaired by LPS exposure, and reverses LPS-induced upregulation of PD-1 on splenic T cells. Anti-Mouse IFN Beta Antibody (MIB-5E9.1) reduces LPS-induced upregulation of GITR on splenic T cells and inhibits LPS-mediated Treg priming.
For research use only. We do not sell to patients.
- Purity : 96.41%
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Armenian Hamster IgG
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
[1]|
IFN-β |
PD-1 |
In Vitro
Anti-Mouse IFN Beta Antibody (MIB-5E9.1) (5 μg/mL; 2 h pre-incubation, 12 h LPS treatment) inhibits LPS-induced B7H1 up-regulation in murine bone marrow-derived dendritic cells[1].
Anti-Mouse IFN Beta Antibody (MIB-5E9.1) (5 μg/mL; 12 h LPS treatment, 3 d co-culture) restores LPS-impaired T cell proliferation induced by murine bone marrow-derived dendritic cells in vitro[1].
Anti-Mouse IFN Beta Antibody (MIB-5E9.1) (5 μg/mL; 2 h pre-incubation, 12 h LPS treatment) inhibits LPS-induced GITRL up-regulation in murine bone marrow-derived dendritic cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:T cells
-
Concentration:5 μg/mL
-
Incubation Time:2 h pre-incubation, 12 h LPS treatment
-
Result:Inhibited the LPS-induced upregulation of GITRL in mouse bone marrow-derived dendritic cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, adaptive immune dysfunction model via adoptive transfer of LPS-treated bone marrow-derived DCs)[1]
-
Dosage:5 mg/mL
-
Administration:in vitro pretreatment; 2 hours (DC pretreatment prior to LPS exposure); treated DCs were injected i.p. into mice
-
Result:Increased Ag-specific CTL priming (measured by IFN-gamma Elispot) compared to LPS-treated DC transfer.
Reduced LPS-induced PD-1 expression in splenic T cells.
Diminished LPS-enhanced GITRL expression in DCs.
Reversed LPS-induced upregulation of GITR in splenic T cells.
Abrogated LPS-induced upregulation of B7H1 in DCs at both protein and mRNA levels.
Gene ID
Accession
P01575
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay, Research in vivo
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse IFN Beta Antibody (MIB-5E9.1) Related Classifications
HY-P991801 Related Classifications
Powered by Bioz